Skip to main content

Table 2 Characteristics of subjects in each cohort

From: Randomized, double-blind, placebo-controlled phase I dose escalation study of Dan Qi Tong Mai tablet in healthy volunteers

ParameterStudyCohortGroup receiving active ingredientsGroup receiving placeboZ*P*
Age (year)Single-dose129.00 (9.59)24.00 (7.07)−0.230.83
221.83 (1.47)22.00 (0.00)0.170.87
323.83 (1.17)22.00 (1.41)−0.690.51
424.00 (2.53)24.50 (3.54)0.001.00
523.83 (2.04)23.00 (1.41)−0.340.75
623.83 (0.98)23.00 (1.41)0.001.00
725.67 (1.97)25.00 (0.00)−0.170.87
824.75 (0.96)24.00 (1.41)−0.480.65
Multiple-dose924.00 (2.28)24.00 (1.41)0.170.87
1023.83 (2.40)23.50 (3.54)0.001.00
1122.50 (1.64)22.50 (0.71)1.700.13
Height (cm)Single-dose1167.00 (8.08)168.50 (12.02)0.001.00
2165.17 (9.85)162.50 (10.61)−0.340.74
3169.17 (7.08)169.00 (15.56)0.001.00
4167.67 (6.98)166.00 (8.45)0.001.00
5168.17 (4.71)166.00 (8.49)−0.170.87
6165.17 (12.06)164.50 (7.78)0.170.87
7166.33 (6.95)167.00 (14.14)0.001.00
8166.50 (6.95)160.00 (0.00)−0.700.48
Multiple-dose9163.00 (9.12)164.00 (5.66)0.340.74
10169.50 (7.45)172.50 (0.71)0.500.62
11167.00 (7.32)159.00 (12.73)−0.670.50
Weight (kg)Single-dose157.75 (9.22)62.00 (14.14)0.460.64
256.33 (10.54)58.00 (4.24)0.500.62
358.83 (10.63)64.00 (12.73)0.670.50
460.83 (8.80)58.50 (9.19)−0.170.86
559.83 (4.31)54.50 (7.78)−1.070.29
658.17 (9.06)56.50 (10.61)−0.510.61
759.00 (7.32)56.50 (13.44)−0.170.87
859.50 (6.66)49.50 (0.71)−1.410.16
Multiple-dose958.17 (12.95)57.50 (3.54)0.001.00
1062.33 (9.35)62.50 (3.54)0.170.87
1160.42 (8.18)54.75 (13.79)−0.500.62
Body mass index (kg/m2)Single-dose120.59 (1.23)21.60 (1.83)1.160.25
220.53 (1.63)22.00 (1.26)0.830.40
320.41 (2.03)22.28 (0.35)1.170.24
421.54 (1.73)21.14 (1.17)−0.170.87
521.14 (1.00)19.72 (0.82)−1.500.13
621.25 (1.47)20.77 (1.96)−0.500.62
721.30 (2.08)20.07 (1.41)−0.830.40
821.40 (0.95)19.34 (0.28)−1.620.11
Multiple-dose921.24 (1.67)21.37 (0.16)0.001.00
1021.58 (1.52)21.01 (1.36)−0.840.40
1121.57 (1.39)21.43 (2.02)0.001.00
  1. Values are mean (SD)
  2. *Wilcoxon test